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A Rare Case of
Prednimustine-Induced
Myoclonus
Prednimustine is frequently used in
the treatment of chronic lymphocytic
leukemia, non-Hodgkin’s lymphoma,
Hodgkin’s disease, and ovarian and
breast cancers. However, care should be
taken to recognize early neurologic side
effects that may have disabling conse-
quences.
We report here a rare neurologic side
effect associated with administration of
prednimustine. A 79-year-old woman
presented with weight loss, night
sweats, asthenia, bilateral inguinal
lymphadenopathy, and splenomegaly.
She had had a 19-year history of low-
grade follicular lymphoma, which had
been treated 8 years previously by vari-
ous chemotherapy regimens, including
prednimustine.
A biopsy of an inguinal adenopathy
disclosed Hodgkin’s disease, histologi-
cally different from the previously
known lymphoma. She was treated with
an oral combination of lomustine at a
dose of 80 mg/m2 on day 1 and etopo-
side at a dose of 100 mg/m2 and pred-
nimustine at a dose of 60 mg/m2, both
given on days 1 to 5 (corresponding to a
total dose of chlorambucil of 6 mg/kg),
and she was premedicated with allopu-
rinol and ondansetron. On day 3, she
noticed abnormal jerks of her hands,
which increased during the subsequent
days and finally involved the four limbs.
On day 6, unable to stand, she fell and
broke her right arm. Neurologic assess-
ment at the emergency room disclosed
severe myoclonia of the four limbs. Her
mental state and conscious state were
normal, and laboratory tests showed no
electrolyte abnormalities. Clonazepam
was introduced, and the myoclonia
gradually decreased and disappeared on
day 8. A medical history revealed that
the patient had experienced the same
hand jerks 8 years before while taking
prednimustine. We replaced prednimus-
tine with prednisone in subsequent treat-
ment cycles, and the myoclonus did not
reappear.
Prednimustine is an ester of prednis-
olone and chlorambucil. Elimination of
chlorambucil and its metabolite phenyl-
acetic mustard is prolonged after oral
administration of prednimustine com-
pared with chlorambucil alone. Neuro-
toxicity was dose limiting in a phase I
trial of high-dose chlorambucil (1), and
chlorambucil-related myoclonus has
been described (2) in a 71-year-old
woman treated for a lymphocytic lym-
phoma with a 5-day regimen of chlor-
ambucil and deltacortisone. In this
patient, the jerks appeared on day 3, cul-
minated on day 7, and disappeared
gradually after another week.
Three cases of prednimustine-in-
duced myoclonus have also been re-
ported (3) in women previously treated
with cisplatin for an ovarian cancer. The
myoclonia developed on day 4 during a
5-day regimen of prednimustine (120
mg/m2 per day) and disappeared after
cessation of the chemotherapy and ad-
ministration of diazepam. Hypomagne-
semia found in these three patients was
considered a possible contributing fac-
tor.
The mechanism of chlorambucil-
induced myoclonus is not known. My-
oclonus arises from the central nervous
system in a complex interaction between
brain stem, cortex, and cerebellum. It is
found in several neurologic diseases, in-
cluding mitochondrial myopathies with
central nervous system dysfunction, in
which deficiencies of components of the
respiratory chain are observed (4).
Similarly, the neurotoxicity of an alkyl-
ating agent (5) is due to the interference
with oxidative phosphorylation in the
mitochondria by their metabolites.
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Circulating Prostate-Specific
Antigen/CD14-Double-Positive
Cells: a Biomarker Indicating
Low Risk for Hematogeneous
Metastasis of Prostate Cancer
The presence of cells in the blood
stream of prostate cancer patients that
stain positively for both prostate-
specific antigen (PSA) and for the
monocyte marker CD14 seems to indi-
cate a low risk of metastasis formation.
This cellular biomarker might be help-
ful in the assessment of the prognosis
for prostate cancer patients with or-
gan-restricted disease. It could be used
to define a subgroup of patients with a
low risk of life-threatening bone me-
tastasis, although these patients show
evidence of circulating prostate cancer
cells by flow cytometry (1) or PSA-
PCR2 (2).
We describe here 16 patients with
N0M0 stage prostate cancer and 11 pa-
tients with prostate cancer with bone
metastasis (stage M1) as well as two
control groups (eight patients with blad-
der cancer and nine patients with be-
nign prostatic hyperplasia). So that we
could determine the number of PSA/
CD14-double-stained cells in the pe-
ripheral blood of the patients by flow
cytometry, 10 mL of EDTA-treated
blood was drawn from the patients by
venipuncture, and the erythrocytes were
depleted by density-gradient centrifuga-
tion. The cells were stained simulta-
neously with anti-PSA–fluorescein
isothiocyanate (FITC) (Coulter-Im-
munotech, Hamburg, Federal Republic
of Germany) and an antibody labeled
with CD14–phycoerythrin (PE) (Di-
anova, Hamburg). Controls for nonspe-
cific binding of the antibody, negative
controls with blood from healthy wo-
men, and positive controls with LNCaP
cells were performed. The PSA-positive
and PSA/CD14-double-positive cells
were counted by a count gate discrimi-
nation procedure adjusted to the exclu-
sion of nonspecific, stained cells in the
FL1 (FITC)/FL2 (PE) plot of the nega-
tive control; two million peripheral
white blood cells were analyzed for each
sample after erythrocyte depletion.
The data in Fig. 1 suggest that the
exclusive detection of molecular signals,
either by immunologic means or by
polymerase chain reaction, representing
PSA-positive cells in the circulation, is
not sufficient to estimate the risk of me-
tastasis in prostate cancer.
We are entering a new period of re-
search on circulating cancer cells. In
1991, Smith et al. (3) introduced the
polymerase chain reaction for tissue-
specific cell detection. Modern tools in
immunology and in molecular biology
now provide a means to unveil the
meaning of circulating cancer cells (4).
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Fig. 1. In patients with N0M0 or M1 stage prostate cancer (PCa), prostate-specific antigen (PSA)-positive
cells (right Y axis) were increased compared with those in the control patients. Only in patients with stage
M1 disease were the PSA/CD14-double-positively stained cells (left Y axis) significantly decreased
compared with those in the control patients (P<.05, paired Wilcoxon test). A statistically significant
increase in PSA/CD14-double-positive cells was measured in patients with M1 stage prostate cancer
compared with patients with N0M0 prostate cancer (P<.01). BPH 4 benign prostatic hyperplasia. Error
bars represent standard deviations.
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